Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- New Year's Greeting
January 1, 2001
- Ministries, Agencies to Be Reorganized
January 1, 2001
- Many Know about Anti-smoking Aids, But They Are Not Commonly Used: Survey
January 1, 2001
- The Year 2000 in RetrospectJapanese Drug Industry at the Mercy of Large Waves of Globalization
January 1, 2001
- CST Report Urges Strengthening Lifestyle-related Disease Research
January 1, 2001
- Hitachi to Provide High Tech Healthcare Services
January 1, 2001
- 'New Opportunities and New Solutions Are within Reach'
January 1, 2001
- REGULATORY NEWS IN BRIEF
January 1, 2001
- Siemens-Asahi Medical to Launch New Maintenance-free Spiral CT
January 1, 2001
- PhRMA Japan Representative Moves to Kamiyacho
January 1, 2001
- Kraft: Consolidated Half-year Sales Mark ¥13.5 Bil.
January 1, 2001
- Additional Safety Measures for Bio-Vascular's Artificial Blood Vessel Ordered
January 1, 2001
- Perspective for the Japanese Pharmaceutical Industry in 2001
January 1, 2001
- AstraZeneca K.K.
January 1, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 1, 2001
- Sankyo to Codevelop Oral Antithrombotic with Lilly
January 1, 2001
- Long-term Administration of PPI Included in Insurance Coverage
January 1, 2001
- Aiming at Sales of ¥350 Bil. to ¥400 Bil. in 2005: Mr Bootes of Pfizer
January 1, 2001
- Mitsubishi-Tokyo Licenses Antiviral Agent MCC-478 to Eli Lilly
January 1, 2001
- Third Parties to Be Allowed to Provide Sperm or Ova for Infertile Couples
January 1, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…